Mira Pharmaceuticals, Inc. completed its acquisition of SKNY Pharmaceuticals, Inc. on 2025-09-29, according to the Form 8-K Mira Pharmaceuticals, Inc. filed with the SEC on 2025-09-30. The filing's Item 2.01 states no aggregate dollar price.
| Acquirer | Mira Pharmaceuticals, Inc. |
|---|---|
| Acquired | SKNY Pharmaceuticals, Inc. |
| Completed | 2025-09-29 |
| Reported by | Mira Pharmaceuticals, Inc. (MIRA), the buyer |
| Filing | Form 8-K, filed 2025-09-30 |
Want the whole picture on Mira Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mira Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mira Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On September 29, 2025, MIRA Pharmaceuticals, Inc. (the "Company") completed its acquisition of SKNY Pharmaceuticals, Inc. ("SKNY") pursuant to the previously announced merger agreement (the "Merger Agreement").
More from the filing
The information contained in Item 1.01 above is incorporated herein. .
Entry into a Material Definitive Agreement On September 29, 2025, MIRA Pharmaceuticals, Inc. (the "Company") completed its acquisition of SKNY Pharmaceuticals, Inc. ("SKNY") pursuant to the previously announced merger agreement (the "Merger Agreement").
At closing, the Company acquired 100% of SKNY in exchange for restricted shares of the Company's common stock, par value $0.0001 per share, issued to the shareholders of SKNY.
Quoted from Mira Pharmaceuticals, Inc.'s Form 8-K.
This is the only completed acquisition Mira Pharmaceuticals, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Mira Pharmaceuticals, Inc.Look up Mira Pharmaceuticals, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.